Relationship of Tissue Factor Pathway Inhibitor Activity to Plasma Lipoproteins and Myocardial Infarction at a Young Age

Elisabeth Moor; Anders Hamsten; Fredrik Karpe; Peter Båvenholm; Margareta Blombäck; Angela Silveira

doi:10.1055/s-0038-1642509

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1994; 71(05): 707-712
DOI: 10.1055/s-0038-1642509

Review Article

Schattauer GmbH Stuttgart

Relationship of Tissue Factor Pathway Inhibitor Activity to Plasma Lipoproteins and Myocardial Infarction at a Young Age

Elisabeth Moor

¹The Divisions of Cardiology, Department of Laboratory Medicine, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden

,

Anders Hamsten

²Internal Medicine, Department of Laboratory Medicine, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden

³The Atherosclerosis Research Unit King Gustaf V Research Institute, Department of Laboratory Medicine, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden

,

Fredrik Karpe

²Internal Medicine, Department of Laboratory Medicine, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden

³The Atherosclerosis Research Unit King Gustaf V Research Institute, Department of Laboratory Medicine, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden

,

Peter Båvenholm

²Internal Medicine, Department of Laboratory Medicine, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden

³The Atherosclerosis Research Unit King Gustaf V Research Institute, Department of Laboratory Medicine, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden

,

Margareta Blombäck

⁴Department of Medicine, and Division of Clinical Chemistry and Blood Coagulation, Department of Laboratory Medicine, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden

,

Angela Silveira

³The Atherosclerosis Research Unit King Gustaf V Research Institute, Department of Laboratory Medicine, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden

› Institutsangaben

Abstract

als PDF herunterladen

Summary

Tissue factor pathway inhibitor (TFPI) activity was quantified in two cohorts of young male post-infarction patients and in population-based control subjects to explore the relationships between TFPI activity and plasma lipoproteins and to address the issue of coordinate regulation of factor VII and TFPI in hyperlipidaemia and premature coronary heart disease (CHD). Participants were investigated in the fasting state and after an oral fat load. Basal TFPI activity and factor VII antigen (VIIag) levels were found to be increased in the patients (TFPI activity 1.25 ± 0.23 vs 1.17 ± 0.20 U/ml, p <0.05; VIIag 537.7 ± 127.7 vs 479.4 ± 93.4 ng/ml, p <0.001). The parallel increase was accounted for by patients with hypertriglyceridaemic lipoprotein phenotypes. In contrast, the level of activated factor VII (VIIa) neither differed significantly between patients and controls, nor between patients with different lipoprotein phenotypes. The elevated TFPI activity in the patients was closely associated with the plasma level of dense low density lipoprotein (LDL) particles (r = 0.46, p <0.001) and with the plasma concentration of the small, dense high density lipoprotein (HDL) subspecies HDL_3b (r = 0.34, p <0.01).

PDF (562 kb)

Referenzen

References
1 Broze Jr GJ. The role of tissue factor pathway inhibitor in a revised coagulation cascade. Semin Hematol 1992; 29: 159-69
2 Broze Jr GJ, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VH-tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action. Blood 1988; 71: 335-43
3 Broze Jr GJ, Girard TJ, Novotny WF. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 1990; 29: 7539-46
4 Davies MJ, Woolf N. Atherosclerosis: What is it and why does it occur?. Br Heart J 1993; 69 (Suppl): S3-S11
5 Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839-43
6 Sandset PM, Simes PA, Abildgaard U. Factor VII and extrinsic pathway inhibitor in acute coronary disease. Br J Haematol 1989; 72: 391-6
7 Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50: 803-13
8 Novotny WF, Girard TJ, Miletich JP, Broze Jr GJ. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem 1989; 264: 18832-7
9 Lesnick P, Vonica A, Guérin M, Moreau M, Chapman MJ. Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a). Arterioscler Thromb 1993; 13: 1066-75
10 Sandset PM, Lund H, Norseth J, Abildgaard U, Ose L. Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system. Arterioscler Thromb 1991; 11: 138-45
11 Silveira A, Karpe F, Blombäck M, Steiner G, Walldius G, Hamsten A. Activation of coagulation factor VII during alimentary lipemia. Arterioscler Thromb 1994; 14: 60-9
12 Scarabin PY, Bara L, Samama M, Orssaud G. Further evidence that activated factor VII is related to plasma lipids. Br J Haematol 1985; 61: 186-7
13 Hamsten A. Studies on myocardial infarction at young age. Metabolic, haemostatic and familial factors in post-infarction patients below the age of 45.. M. D. Thesis. Karolinska Institute; 1986
14 Karpe F, Bard J-M, Steiner G, Carlsson LA, Fruchart J-C, Hamsten A. HDLs and alimentary lipemia. Studies in men with previous myocardial infarction at a young age. Arterioscler Thromb 1993; 13: 11-22
15 Karpe F, Steiner G, Olivecrona T, Carlsson LA, Hamsten A. Metabolism of triglyceride-rich lipoproteins during alimentary lipemia. J Clin Invest 1993; 91: 748-58
16 Hamsten A, Blombäck M, Wiman B, Svensson J, Szamosi A, de Faire U, Mettinger L. Haemostatic function in myocardial infarction. Br Heart J 1986; 55: 58-66
17 Sandset PM, Larsen ML, Abildgaard U, Lindahl AK, Ødegaard OR. Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol. Blood Coag Fibrinol 1991; 2: 425-33
18 Owren PA, Aas K. The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand J Clin Lab Invest 1951; 3: 201-18
19 Carlson K. Lipoprotein fractionation. J Clin Pathol 1973; 5 Suppl (Suppl. 26) 32-7
20 Tornvall P, Karpe F, Carlson LA, Hamsten A. Relationships of low density lipoprotein subfractions to angiographically defined coronary artery disease in young survivors of myocardial infarction. Atherosclerosis 1991; 90: 67-80
21 Chapman MJ, Laplaud PM, Luc G, Forgez P, Biuckert E, Guulinet S, Lagrange D. Further resolution of the low density lipoprotein spectrum in normal human plasma: physicochemical characteristics of discrete subspecies separated by density gradient ultracentrifugation. J Lipid Res 1988; 29: 442-58
22 Johansson J, Carlson LA, Landou C, Hamsten A. High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic subjects. Arterioscler Thromb 1991; 11: 174-82
23 Blanche PJ, Gong EL, Forte TM, Nichols AV. Characterization of human high density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta 1981; 665: 408-19
24 Zlatkis A, Zak B, Boyle A. A new method for direct determination of serum cholesterol. J Lab Clin Med 1953; 41: 486-92
25 Fletcher MJ. A colorimetric method for estimating serum triglycerides. Clin Chim Acta 1968; 22: 393-7
26 Carlson LA. Determination of serum triglycerides. J Atheroscler Res 1963; 3: 334-6
27 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin fenol reagent. J Biol Chem 1951; 193: 265-75
28 Poapst M, Uffelman K, Steiner G. The chromogenicity and quantitation of apo B-100 and apo B-48 of human plasma lipoproteins on analytical SDS gel electrophoresis. Atherosclerosis 1987; 65: 75-88
29 Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze Jr GJ. Plasma antigen levels of lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991; 78: 387-93
30 Warr TA, Warn-Cramer BJ, Rao LVM, Rapaport SI. Human plasma extrinsic pathway inhibitor activity: I. Standardization of assay and evaluation of physiologic variables. Blood 1989; 74: 201-6
31 Sandset PM, Hpgevold HE, Lyberg T, Andersson TR, Abildgaard U. Extrinsic pathway inhibitor in elective surgery: a comparison with other coagulation inhibitors. Thromb Haemost 1989; 62: 856-60
32 Bajaj MS, Rana SV, Wysolmerski RB, Bajaj SP. Inhibitor of the factor Vlla-tissue factor complex is reduced in patients with disseminated intravascular coagulation but not in patients with severe hepatocellular disease. J Clin Invest 1987; 79: 1874-8
33 Lindahl AK, Sandset PM, Abildgaard U, Andersson TR, Harbitz TB. High plasma levels of extrinsic pathway inhibitor and low levels of other coagulation inhibitors in advanced cancer. Acta Chir Scand 1989; 155: 389-93
34 Lesnik P, Rouis M, Skarlatos S, Kruth HS, Chapman MJ. Uptake of exogenous free cholesterol induces upregulation of tissue factor expression in human monocyte-derived macrophages. Proc Natl Acad Sci USA 1992; 89: 10370-4
35 Witztum JL, Steinberg D. Role of oxidized LDL in atherogenesis. J Clin Invest 1991; 88: 1785-92
36 Tribble DL, IIoll LG, Wood TD, Krauss RM. Variations in the oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 1992; 93: 189-99
37 De Graaf J, Hak-Lemmers HLM, Hectors MPC, Demacker PNM, Hendricks JCM, Stalenhoef AFH. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991; 11: 298-306
38 Dejagei S, Biuckeit E, Chapman MJ. Dense low-density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res 1993; 34: 295-308
39 Lindahl AK, Abildgaard U, Larsen ML, Staalesen R, Hammer AKG, Sandset PM, Nordfang O, Beck TC. Extrinsic pathway inhibitor (EPI) released to the blood by heparin is a more powerful coagulation inhibitor than is recombinant EPI. Thromb Res 1991; 62: 607-14
40 Lindahl AK, Jacobsen PB, Sandset PM, Abildgaard U. Tissue factor pathway inhibitor with high anticoagulant activity is increased in postheparin plasma and in plasma from cancer patients. Blood Coag Fibrinol 1991; 2: 713-21